RecruitingNot Applicable

Dumping Syndrome and Esophageal Atresia

France15 participantsStarted 2024-02-23

Plain-language summary

Dumping syndrome (DS) is frequent in oesophageal atresia (29%). In causing hypoglycaemia, it can be dangerous for neonates. Mechanisms of DS are actually partialy understood. This is also an affection difficult to diagnose, because it only occurs after meals and can be inconstantly present. To date, their is only symptomatic treatment for DS. This study aims to understand its pathological mechanisms so as to better treat it and avoid its consequences. Oesophageal atresia patients enrolled in this study will benefit from a continuous glycemic monitoring, a continuous cardiac monitoring, and an a gastric emptying scintigraphy at the age of 3 months

Who can participate

Age range2 Months – 3 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients operated at birth for Oesophageal atresia type C * Aged from 2 to 3 months at inclusion * Off prokinetic treatment (suspended for at least 72 hours) before monitoring Exclusion Criteria: * History of dumping syndrome of other cause (microgastria, fundoplication, dysautonomia..) * History of any disease that can modify glycemic regulation (hyperinsulinism, neonatal diabete) * Treatment that can modify gastric motility

What they're measuring

Abnormal glycaemia associated with vagal hypertonia

Timeframe: At least once during the 48 hours monitoring

Trial details

NCT IDNCT04522193

SponsorUniversity Hospital, Lille

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-11

Contact for this trial

Madelaine AUMAR, MD

0320445962 madeleine.aumar@chru-lille.fr

View on ClinicalTrials.gov More Oesophageal Atresia trials